| Autor: |
Saucedo-Uribe, Erasmo, González-Mallozzi, Pedro Jehu, Medrano-Garza, Raúl Ricardo, Díaz González-Colmenero, Fernando, Carranza-Navarro, Farid, Castillo-Morales, Patricia Lizeth, Leyva-Camacho, Paloma C., Herrera-Montemayor, Yessica, Vidal-Tijerina, Mauricio, Enríquez-Navarro, Moisés Karika, Medrano, Samantha B., Fernández-Zambrano, Stefan Mauricio, Mancías-Guerra, Claudia Magdalena, Saucedo-Mancías, Claudia Lizeth, Sánchez-Ramírez, Manuel Ramiro |
| Předmět: |
|
| Zdroj: |
Archivos de Neurociencias; jun2023, Vol. 28 Issue 2, p35-43, 9p |
| Abstrakt: |
Introduction: Long-acting injectable antipsychotics (LAIA) can influence the course of treatment and have the potential to improve treatment adherence. This systematic review and network meta-analysis aimed to evaluate the efficacy of second-generation LAIAs (SG-LAIAs) and first-generation LAIAs (FG-LAIAs) in the treatment of schizophrenia. Methods: The present study adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and is registered in Prospero (ID CRD42019128700). A comprehensive search was conducted in Medline, Embase, Web of Science, and Scopus databases. The search encompassed the period from June 17, 2020, with an update from June 2020 until September 14, 2021. Results: The standardized mean differences (SMDs) for four antipsychotics (80%) demonstrated significant reductions in PANSS scores compared to the placebo. The SMDs ranged from -0.72 (95% CrI -0.99 to -0.46) for haloperidol to -0.45 (-0.54 to -0.37) for paliperidone. Eight studies provided usable results for both negative and positive symptoms, involving a comparison of four antipsychotics. The SMDs for three antipsychotics (75%) significantly reduced negative symptoms compared to placebo, ranging from -0.40 (95% CrI -0.53 to -0.26) for aripiprazole to -0.32 (-0.44 to -0.19) for risperidone. The SMDs for the three drugs (100%) that significantly reduced positive symptoms compared to placebo ranged from -0.50 (95% CrI -0.63 to -0.37) for aripiprazole to -0.19 (-0.57 to 0.20) for zuclopenthixol. Discussion: Our findings suggest that all long-acting injectable antipsychotics, except for zuclopenthixol, exhibit comparable efficacy in symptom reduction. Conclusions: The majority of LAIAs demonstrate similar effectiveness in reducing overall symptoms, and the differences between individual LAIAs are not statistically significant. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
